Breast Imaging

Which Imaging Is Best for Staging Stage IIB-III HER2+ or Triple-Negative Breast Cancer?

·
Which Imaging Is Best for Staging Stage IIB-III HER2+ or Triple-Negative Breast Cancer?

A 48-year-old woman presents to your clinic with a new diagnosis of a 4 cm, node-positive, triple-negative invasive ductal carcinoma. Her clinical stage is IIIA (T2, N1). Before her multidisciplinary team can finalize a neoadjuvant chemotherapy plan, they need to definitively rule out distant metastatic disease. You know that for this high-risk combination of tumor size, nodal involvement, and aggressive biology, the pre-test probability of metastases is significant. The critical question is which imaging studies will most accurately and efficiently complete her systemic staging. According to the American College of Radiology (ACR) Appropriateness Criteria, for this specific scenario, a Bone scan whole body is rated Usually appropriate, alongside contrast-enhanced CT and FDG-PET/CT, to evaluate for the most common sites of distant spread.

## Who Fits This Clinical Scenario for Breast Cancer Staging?
This guidance applies specifically to patients with newly diagnosed invasive breast cancer who meet a precise combination of anatomic stage and tumor biology criteria that place them at high risk for distant metastases at presentation.

Inclusion criteria for this workflow:

  • Diagnosis: Newly diagnosed invasive ductal carcinoma (IDC) or invasive lobular carcinoma (ILC).
  • Clinical Stage: Stage IIB (e.g., T2N1, T3N0) through Stage III (e.g., T3N1, any T4, any N2, or any N3). This is considered locally advanced or “late-stage” disease.
  • Tumor Biology: The cancer must have an aggressive phenotype, defined as either HER2-positive (HER2+) or triple-negative (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative).

Exclusion criteria (patients who require a different imaging pathway):

  • Early-Stage Disease: Patients with clinical stage I or IIA breast cancer have a much lower risk of distant metastases, and systemic staging is generally not recommended. Their workup focuses on locoregional disease.
  • Hormone Receptor-Positive, HER2-Negative Late-Stage Disease: While still late-stage, these less aggressive tumors have a different risk profile and may follow a slightly different staging algorithm.
  • Evaluation for Locoregional Disease: If the primary clinical question is to assess the extent of disease within the breast and regional lymph nodes (e.g., for surgical planning), breast MRI is often the modality of choice, not the systemic staging studies discussed here.
  • Surveillance After Treatment: This guidance is for initial staging only. Imaging to detect recurrence in an asymptomatic patient after completion of therapy follows separate surveillance guidelines.

## What Distant Metastases Are You Working Up in High-Risk Breast Cancer?
For patients with locally advanced, aggressive breast cancer, the goal of systemic staging is to detect metastatic deposits before initiating curative-intent therapy. The imaging strategy is designed to interrogate the most common and clinically significant sites of spread.

Bone Metastases
The skeleton is the most frequent site of distant disease in breast cancer. Metastases are typically osteoblastic or mixed lytic-blastic. Identifying bone involvement is critical as it immediately upstages the patient to Stage IV, changes the treatment goal from curative to palliative, and may require specific bone-targeted therapies (e.g., bisphosphonates, denosumab) and potentially radiation to prevent or treat pain and pathologic fractures.

Visceral Metastases (Liver and Lungs)
The liver and lungs are the next most common sites of hematogenous spread. Aggressive subtypes like triple-negative and HER2-positive breast cancer have a higher propensity for visceral involvement. Liver metastases can be asymptomatic until they are extensive, while pulmonary metastases may present with subtle cough or dyspnea, if at all. Cross-sectional imaging is essential for their detection.

Distant Nodal Metastases
While axillary lymph node status defines the regional “N” stage, the spread of cancer to distant, non-regional lymph node basins constitutes metastatic disease. This includes contralateral axillary, internal mammary, supraclavicular, or mediastinal nodes. Identifying involvement in these areas is crucial for accurate staging and radiation therapy planning.

Brain Metastases
Although less common at initial diagnosis compared to bone or visceral sites, brain metastases are a significant concern in patients with HER2-positive and triple-negative subtypes. Routine screening with brain imaging is not typically performed in asymptomatic patients, but the threshold to order a head MRI or CT should be low if any neurologic symptoms are present.

## Why Are Bone Scan, CT, and PET/CT Recommended for Staging This Presentation?
For this high-risk scenario, the ACR rates three distinct imaging strategies as Usually appropriate: a whole-body bone scan, a CT of the chest, abdomen, and pelvis with IV contrast, and an FDG-PET/CT scan. The optimal choice often depends on institutional preference, availability, and the desire for a single comprehensive study versus a combination of tests.

A Bone scan whole body is a foundational study for this workup. It uses a radiotracer (technetium-99m methylene diphosphonate) that accumulates in areas of high bone turnover, making it highly sensitive for detecting osteoblastic skeletal metastases. It provides a complete survey of the skeleton with a relatively moderate radiation dose (ACR RRL ☢☢☢, 1-10 mSv). Its primary limitation is that it cannot evaluate soft tissues or viscera, and benign processes like arthritis or healing fractures can cause false-positive findings.

A CT chest, abdomen, and pelvis with IV contrast is also rated Usually appropriate because it directly addresses the bone scan’s main limitation: the inability to assess for visceral or soft tissue disease. This single study effectively screens the lungs, liver, adrenal glands, and distant lymph node basins. However, it is less sensitive than a bone scan for early bone metastases and involves a higher radiation dose (ACR RRL ☢☢☢☢, 10-30 mSv). For many years, the combination of a bone scan and a contrast-enhanced CT was the standard of care for systemic staging.

An FDG-PET/CT from skull base to mid-thigh has emerged as a powerful, single-modality alternative, also rated Usually appropriate. By fusing metabolic data from the PET scan with anatomic data from the CT, it can detect bone, visceral, and nodal metastases in one session. It is often considered more sensitive and specific than the combination of bone scan and CT, particularly for detecting lytic bone lesions and unexpected sites of disease. The main considerations are its higher cost, limited availability in some regions, and a significant radiation dose (ACR RRL ☢☢☢☢, 10-30 mSv).

Why are other studies rated lower for this specific purpose?

  • MRI breast without and with IV contrast: This is rated Usually not appropriate for evaluating distant disease. Its strength is in defining the extent of the primary tumor and identifying additional disease within the breast (locoregional staging), not in screening the liver, lungs, or bones.
  • US axilla or US breast: These are also Usually not appropriate for systemic staging. Ultrasound is excellent for evaluating the primary tumor and assessing regional lymph nodes but lacks the field of view and capability to screen for distant metastases.

Once you’ve decided on a Bone scan whole body, our protocol guide covers the technique, radiotracer, and reading principles: Nuclear Medicine Bone Scan (Whole Body).

## What’s Next After Staging Scans? Downstream Workflow
The results of your systemic staging studies will fundamentally alter the patient’s treatment plan and prognosis. The workflow branches based on whether distant disease is identified.

  • If studies are positive for distant metastases: The patient is upstaged to Stage IV (metastatic) breast cancer. The treatment intent shifts from curative to palliative. The patient will typically proceed with systemic therapy (chemotherapy, targeted therapy, and/or endocrine therapy) rather than locoregional surgery or radiation, although these may be used for symptom control. Biopsy of a suspicious metastatic site may be required for confirmation, especially if it is an isolated finding.
  • If studies are negative for distant metastases: The patient’s clinical stage (IIB-III) is confirmed. They can proceed with curative-intent therapy, which for this patient population often involves neoadjuvant (pre-operative) systemic therapy followed by surgery (lumpectomy or mastectomy) and radiation. The negative staging results provide the green light to begin this intensive local and systemic treatment regimen.
  • If studies are indeterminate: An equivocal finding is a common clinical challenge. For example, a single focus of uptake on a bone scan in a location common for degenerative change. The next step is problem-solving with a different modality. An MRI of the specific area can often differentiate a benign process from a metastasis. For an indeterminate liver lesion on CT, an MRI or biopsy may be necessary. The goal is to resolve the ambiguity before committing the patient to a major treatment pathway.

## Pitfalls to Avoid (and When to Get Help)

  • Under-staging: Failing to perform systemic staging in this high-risk population is a critical error. The assumption that locally advanced, aggressive disease is confined to the breast and axilla is unsafe.
  • Misinterpreting Benign Findings: A bone scan can light up for many reasons besides cancer, including arthritis, trauma, and infection. Correlating with patient history and using problem-solving imaging for solitary, equivocal lesions is key to avoiding a false-positive diagnosis of metastatic disease.
  • Omitting IV Contrast: When ordering a staging CT, failing to specify “with IV contrast” severely limits its ability to detect liver metastases and characterize lymph nodes.
  • Ignoring Neurologic Symptoms: Do not rely on whole-body staging to evaluate the brain. If a patient with HER2+ or triple-negative disease reports headaches, seizures, or focal deficits, a dedicated brain MRI should be ordered immediately, independent of systemic staging.

If staging results are complex or contradictory, a discussion at a multidisciplinary tumor board—including medical oncology, surgical oncology, radiation oncology, and radiology—is the best way to achieve consensus on the patient’s definitive stage and treatment plan.

## Related ACR Topics and Tools
For a comprehensive overview of imaging across all breast cancer scenarios, from early-stage to surveillance, see our parent guide. It provides the breadth that complements this article’s depth.

For additional tools to help with ordering decisions and patient communication, explore these resources:

Frequently Asked Questions

Why is FDG-PET/CT not always the first choice if it’s the most comprehensive test?

While FDG-PET/CT is an excellent all-in-one staging tool, its use can be limited by higher cost, insurance pre-authorization requirements, and lower availability compared to CT and bone scans. In many health systems, a combination of bone scan and CT chest/abdomen/pelvis with contrast remains a cost-effective and clinically robust alternative that is also rated ‘Usually appropriate’ by the ACR.

If my patient has Stage IIB HER2+ breast cancer, do I need to order a brain MRI for staging?

No, not for an asymptomatic patient. While HER2-positive and triple-negative breast cancers have a higher risk of brain metastases, the ACR and other guidelines do not recommend routine brain imaging for initial staging in the absence of neurologic symptoms. The yield is too low to justify routine screening.

What if the biopsy shows invasive lobular carcinoma (ILC) instead of IDC? Does the staging change?

No, the recommended staging workup for distant disease is the same. This guidance applies to both invasive ductal and invasive lobular carcinoma. While ILC has different patterns of local growth and metastasis (e.g., peritoneal spread), the initial screening for distant bone and visceral disease follows the same principles for Stage IIB-III, aggressive-subtype cancers.

The bone scan showed a single spot of uptake in the lumbar spine. What should I do?

An isolated finding on a bone scan is a common dilemma. It requires further characterization to distinguish a benign process (like degenerative joint disease) from a solitary metastasis. The most appropriate next step is typically a targeted MRI of the lumbar spine, which is highly effective at differentiating benign from malignant bone lesions. A CT scan of the area can also be helpful, particularly for characterizing sclerotic lesions.

Is a chest X-ray sufficient to screen for lung metastases in this scenario?

No, a chest X-ray is not sufficient for staging in this high-risk population. A CT of the chest is significantly more sensitive for detecting small pulmonary nodules and evaluating mediastinal lymph nodes. The ACR rates a CT chest with IV contrast as ‘Usually appropriate,’ while a chest radiograph is not listed as an adequate staging study for this clinical scenario.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026